Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

One somewhat unusual, though minor, facet of the March portfolio that differs with most previous editions is that two stocks—Taiwan Semiconductor Manufacturing and Novo Nordisk—hold between 3% ...